Black Diamond Financial LLC Has $467,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Black Diamond Financial LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,885 shares of the company’s stock after acquiring an additional 138 shares during the quarter. Black Diamond Financial LLC’s holdings in Johnson & Johnson were worth $467,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in Johnson & Johnson during the first quarter worth about $765,000. Empowered Funds LLC grew its stake in Johnson & Johnson by 46.7% during the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after buying an additional 32,244 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its stake in Johnson & Johnson by 2.7% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 65,007 shares of the company’s stock worth $10,283,000 after buying an additional 1,689 shares in the last quarter. Schneider Downs Wealth Management Advisors LP grew its stake in Johnson & Johnson by 85.8% during the first quarter. Schneider Downs Wealth Management Advisors LP now owns 3,818 shares of the company’s stock worth $604,000 after buying an additional 1,763 shares in the last quarter. Finally, Barings LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $217,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $175.94.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.9 %

Shares of NYSE JNJ opened at $151.86 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a 50 day simple moving average of $161.82 and a 200 day simple moving average of $155.99. The firm has a market cap of $365.62 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter last year, the business earned $2.66 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.27%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.